Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

The Clinical Impact of a Negative Molecular β-Lactamase Gene Test for Enterobacteriaceae: Let's Not Let Perfect Be the Enemy of Really Good.

Pogue JM, Heil EL.

J Clin Microbiol. 2020 Mar 25;58(4). pii: e02098-19. doi: 10.1128/JCM.02098-19. Print 2020 Mar 25. No abstract available.

PMID:
32213578
2.

The Economics of Penicillin Allergy Testing: Still Scratching the Value Surface.

Mattingly Ii TJ, Heil EL.

Clin Infect Dis. 2020 Feb 28. pii: ciaa195. doi: 10.1093/cid/ciaa195. [Epub ahead of print] No abstract available.

PMID:
32107529
3.

Antimicrobial usage at a large teaching hospital in Lusaka, Zambia.

Masich AM, Vega AD, Callahan P, Herbert A, Fwoloshi S, Zulu PM, Chanda D, Chola U, Mulenga L, Hachaambwa L, Pandit NS, Heil EL, Claassen CW.

PLoS One. 2020 Feb 10;15(2):e0228555. doi: 10.1371/journal.pone.0228555. eCollection 2020.

4.

Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock.

Masich AM, Kalaria SN, Gonzales JP, Heil EL, Tata AL, Claeys KC, Patel D, Gopalakrishnan M.

Pharmacotherapy. 2020 Mar;40(3):211-220. doi: 10.1002/phar.2367. Epub 2020 Feb 5.

PMID:
31957057
5.

A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.

Kalaria SN, Gopalakrishnan M, Heil EL.

Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e02093-19. doi: 10.1128/AAC.02093-19. Print 2020 Feb 21.

PMID:
31871076
6.

Self-perceived knowledge and confidence regarding infectious diseases of advanced pharmacy practice experience students.

Johnson MA, Jones BM, Heil EL, Stover KR, Trone S, Fulford M, Bland CM.

Curr Pharm Teach Learn. 2019 Nov;11(11):1095-1102. doi: 10.1016/j.cptl.2019.07.019. Epub 2019 Aug 12.

PMID:
31783954
7.

Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world.

Pogue JM, Heil EL.

Expert Opin Pharmacother. 2019 Dec;20(17):2053-2057. doi: 10.1080/14656566.2019.1663827. Epub 2019 Sep 8. No abstract available.

PMID:
31496320
8.

Cognitive biases and knowledge deficits leading to delayed recognition of cryptococcal meningitis.

Deming M, Mark A, Nyemba V, Heil EL, Palmeiro RM, Schmalzle SA.

IDCases. 2019 Jul 5;18:e00588. doi: 10.1016/j.idcr.2019.e00588. eCollection 2019.

9.

Clinical outcomes of valganciclovir prophylaxis in high-risk (D+/R-) renal transplant recipients experiencing delayed graft function.

Freedman SR, Ravichandran BR, Masters BM, Bromberg JS, Haririan A, Saharia KK, Heil EL, Sparkes T.

Transpl Infect Dis. 2019 Aug;21(4):e13125. doi: 10.1111/tid.13125. Epub 2019 Jun 25.

PMID:
31165548
10.

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.

Bork JT, Heil EL, Berry S, Lopes E, Davé R, Gilliam BL, Amoroso A.

Infect Dis Ther. 2019 Jun;8(2):171-184. doi: 10.1007/s40121-019-0247-0. Epub 2019 May 3.

11.

A practical guide for pharmacists to successfully implement penicillin allergy skin testing.

Bland CM, Bookstaver PB, Griffith NC, Heil EL, Jones BM, Ann Justo J, Staicu ML, Torney NP, Wall GC.

Am J Health Syst Pharm. 2019 Jan 25;76(3):136-147. doi: 10.1093/ajhp/zxy043. Review.

PMID:
30689753
12.

Penicillin skin testing in methicillin-sensitive staphylococcus aureus bacteremia: A cost-effectiveness analysis.

Mattingly TJ 2nd, Meninger S, Heil EL.

PLoS One. 2019 Jan 7;14(1):e0210271. doi: 10.1371/journal.pone.0210271. eCollection 2019.

13.

Validation of an Antimicrobial Stewardship-Driven Verigene Blood-Culture Gram-Negative Treatment Algorithm to Improve Appropriateness of Antibiotics.

Claeys KC, Schlaffer KE, Heil EL, Leekha S, Johnson JK.

Open Forum Infect Dis. 2018 Sep 15;5(10):ofy233. doi: 10.1093/ofid/ofy233. eCollection 2018 Oct.

14.

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study.

Gallagher JC, Satlin MJ, Elabor A, Saraiya N, McCreary EK, Molnar E, El-Beyrouty C, Jones BM, Dixit D, Heil EL, Claeys KC, Hiles J, Vyas NM, Bland CM, Suh J, Biason K, McCoy D, King MA, Richards L, Harrington N, Guo Y, Chaudhry S, Lu X, Yu D.

Open Forum Infect Dis. 2018 Oct 31;5(11):ofy280. doi: 10.1093/ofid/ofy280. eCollection 2018 Nov.

15.

The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.

Plazak ME, Tamma PD, Heil EL.

Expert Opin Pharmacother. 2018 Dec;19(18):2019-2031. doi: 10.1080/14656566.2018.1538354. Epub 2018 Nov 5. Review.

PMID:
30346216
16.

Making the change to area under the curve-based vancomycin dosing.

Heil EL, Claeys KC, Mynatt RP, Hopkins TL, Brade K, Watt I, Rybak MJ, Pogue JM.

Am J Health Syst Pharm. 2018 Dec 15;75(24):1986-1995. doi: 10.2146/ajhp180034. Epub 2018 Oct 17. No abstract available.

PMID:
30333114
17.

Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients.

Vega AD, Hynicka LM, Claeys K, Chua JV, Heil EL.

Antivir Ther. 2019;24(1):11-17. doi: 10.3851/IMP3263.

PMID:
30192231
18.

Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia.

Lewis PO, Heil EL, Covert KL, Cluck DB.

J Clin Pharm Ther. 2018 Oct;43(5):614-625. doi: 10.1111/jcpt.12743. Epub 2018 Jul 12. Review.

PMID:
30003555
19.

Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.

Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01008-18. doi: 10.1128/AAC.01008-18. Print 2018 Sep.

20.

Best Care for Patients Achieved Through Multidisciplinary Stewardship.

Dodds Ashley E, Davis SL, Heil EL, LaPlante KL, Chahine EB, Bosso JA.

Clin Infect Dis. 2018 Oct 30;67(10):1637. doi: 10.1093/cid/ciy392. No abstract available.

PMID:
29767682
21.

Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention.

Claeys KC, Hopkins TL, Vega AD, Heil EL.

Curr Infect Dis Rep. 2018 Mar 23;20(5):7. doi: 10.1007/s11908-018-0615-z. Review.

PMID:
29572691
22.

An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two Cities.

Pogue JM, Heil EL, Lephart P, Johnson JK, Mynatt RP, Salimnia H, Claeys KC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02538-17. doi: 10.1128/AAC.02538-17. Print 2018 May.

23.

The Verigene dilemma: gram-negative polymicrobial bloodstream infections and clinical decision making.

Claeys KC, Heil EL, Pogue JM, Lephart PR, Johnson JK.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):144-146. doi: 10.1016/j.diagmicrobio.2018.01.012. Epub 2018 Feb 2.

PMID:
29449043
24.

The Cost of Self-Reported Penicillin Allergy: A Systematic Review.

Mattingly TJ 2nd, Fulton A, Lumish RA, Williams AMC, Yoon S, Yuen M, Heil EL.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1649-1654.e4. doi: 10.1016/j.jaip.2017.12.033. Epub 2018 Jan 31.

25.

Accuracy of Provider-Selected Indications for Antibiotic Orders.

Heil EL, Pineles L, Mathur P, Morgan DJ, Harris AD, Srinivasan A, Thom KA; CDC Prevention Epicenters.

Infect Control Hosp Epidemiol. 2018 Jan;39(1):111-113. doi: 10.1017/ice.2017.277.

26.

Peer Comparison of Anti-MRSA Agent Prescription in the Inpatient Setting.

Bork JT, Morgan DJ, Heil EL, Pineles L, Kleinberg M.

Infect Control Hosp Epidemiol. 2017 Dec;38(12):1506-1508. doi: 10.1017/ice.2017.219. Epub 2017 Oct 25.

PMID:
29067897
27.

Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae.

Bork JT, Heil EL, Leekha S, Fowler RC, Hanson ND, Majumdar A, Johnson JK.

Diagn Microbiol Infect Dis. 2017 Dec;89(4):328-333. doi: 10.1016/j.diagmicrobio.2017.08.020. Epub 2017 Oct 12.

PMID:
29031525
28.

Predictors of Adverse Outcomes in Children With Staphylococcus aureus Bacteremia.

Kumarachandran G, Johnson JK, Shirley DA, Graffunder E, Heil EL.

J Pediatr Pharmacol Ther. 2017 May-Jun;22(3):218-226. doi: 10.5863/1551-6776-22.3.218.

29.

Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.

Mattingly Ii TJ, Heil EL, Hoke KS.

J Health Care Poor Underserved. 2017;28(2):621-625. doi: 10.1353/hpu.2017.0062.

PMID:
28529212
30.

Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population.

Kishk OA, Lardieri AB, Heil EL, Morgan JA.

J Pediatr Pharmacol Ther. 2017 Jan-Feb;22(1):41-47. doi: 10.5863/1551-6776-22.1.41. Erratum in: J Pediatr Pharmacol Ther. 2019 Jul-Aug;24(4):374.

31.

Appropriate Antibiotic Therapy.

Allison MG, Heil EL, Hayes BD.

Emerg Med Clin North Am. 2017 Feb;35(1):25-42. doi: 10.1016/j.emc.2016.08.003. Review.

PMID:
27908336
32.

Advancing interprofessional patient safety education for medical, nursing, and pharmacy learners during clinical rotations.

Thom KA, Heil EL, Croft LD, Duffy A, Morgan DJ, Johantgen M.

J Interprof Care. 2016 Nov;30(6):819-822. Epub 2016 Aug 11.

PMID:
27715352
33.

Allergy profile should be updated after uneventful administration of a penicillin or penicillin-related antibiotic to a patient with penicillin allergy.

Oliver WD, Heil EL, Thom KA, Martinez JP, Hayes BD.

J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):184-186. doi: 10.1016/j.jaip.2016.08.011. Epub 2016 Oct 17. No abstract available.

PMID:
27765460
34.

Implementation of an Infectious Disease Fellow-Managed Penicillin Allergy Skin Testing Service.

Heil EL, Bork JT, Schmalzle SA, Kleinberg M, Kewalramani A, Gilliam BL, Buchwald UK.

Open Forum Infect Dis. 2016 Jul 23;3(3):ofw155. eCollection 2016 Sep.

35.

The Essential Role of Pharmacists in Antimicrobial Stewardship.

Heil EL, Kuti JL, Bearden DT, Gallagher JC.

Infect Control Hosp Epidemiol. 2016 Jul;37(7):753-4. doi: 10.1017/ice.2016.82. Epub 2016 Apr 13. No abstract available.

PMID:
27072411
36.

Agricultural Applications for Antimicrobials. A Danger to Human Health: An Official Position Statement of the Society of Infectious Diseases Pharmacists.

Aitken SL, Dilworth TJ, Heil EL, Nailor MD.

Pharmacotherapy. 2016 Apr;36(4):422-32. doi: 10.1002/phar.1737. Epub 2016 Apr 1.

PMID:
26954889
37.

Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.

D'Angelo RG, Johnson JK, Bork JT, Heil EL.

Expert Opin Pharmacother. 2016;17(7):953-67. doi: 10.1517/14656566.2016.1154538. Epub 2016 Mar 3. Review.

PMID:
26891857
38.

Hepatitis C Treatment Exposed or Experienced?

Hynicka LM, Heil EL.

Ann Pharmacother. 2016 Apr;50(4):328. doi: 10.1177/1060028016628542. Epub 2016 Jan 29. No abstract available.

PMID:
26825645
39.

Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.

Heil EL, Johnson JK.

J Clin Microbiol. 2016 Apr;54(4):840-4. doi: 10.1128/JCM.02424-15. Epub 2016 Jan 20.

40.

Impact of Changes in Urine Culture Ordering Practice on Antimicrobial Utilization in Intensive Care Units at an Academic Medical Center.

Sarg M, Waldrop GE, Beier MA, Heil EL, Thom KA, Preas MA, Johnson JK, Harris AD, Leekha S.

Infect Control Hosp Epidemiol. 2016 Apr;37(4):448-54. doi: 10.1017/ice.2015.334. Epub 2016 Jan 18.

41.

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Oliver WD, Heil EL, Gonzales JP, Mehrotra S, Robinett K, Saleeb P, Nicolau DP.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1899-901. doi: 10.1128/AAC.02608-15.

42.

Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass.

Hollis AL, Heil EL, Nicolau DP, Odonkor P, Dowling TC, Thom KA.

Surg Infect (Larchmt). 2015 Dec;16(6):829-32. doi: 10.1089/sur.2014.250. Epub 2015 Aug 20.

PMID:
26291478
43.

What does the pharmacological future of treating chronic hepatitis C look like?

Heil EL, Hynicka LM, Kottilil S, Tang L.

Expert Rev Clin Pharmacol. 2015;8(5):605-22. doi: 10.1586/17512433.2015.1074859. Epub 2015 Aug 6. Review.

PMID:
26289223
44.

Resistance Patterns of Escherichia coli in Women with Uncomplicated Urinary Tract Infection Do Not Correlate with Emergency Department Antibiogram.

Hines MC, Al-Salamah T, Heil EL, Mallemat H, Witting MD, Johnson JK, Winters ME, Hayes BD.

J Emerg Med. 2015 Dec;49(6):998-1003. doi: 10.1016/j.jemermed.2015.06.028. Epub 2015 Aug 15.

PMID:
26281821
45.

A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.

Nguyen AD, Heil EL, Patel NK, Duffy A, Gilmore S.

J Oncol Pharm Pract. 2016 Apr;22(2):303-7. doi: 10.1177/1078155214567161. Epub 2015 Jan 7.

PMID:
25567517
46.

Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.

Heil EL, Lowery AV, Thom KA, Nicolau DP.

Pharmacotherapy. 2015 Jan;35(1):54-8. doi: 10.1002/phar.1514. Epub 2014 Dec 29.

PMID:
25556715
47.

Rapid testing using the Verigene Gram-negative blood culture nucleic acid test in combination with antimicrobial stewardship intervention against Gram-negative bacteremia.

Bork JT, Leekha S, Heil EL, Zhao L, Badamas R, Johnson JK.

Antimicrob Agents Chemother. 2015 Mar;59(3):1588-95. doi: 10.1128/AAC.04259-14. Epub 2014 Dec 29.

48.

CDC antibiotic stewardship recommendations: One state's assessment identifies need for compliance.

Heil EL, Thomas J.

Am J Health Syst Pharm. 2014 Nov 1;71(21):1833-4. doi: 10.2146/ajhp140273. No abstract available.

PMID:
25320131
49.

Ceftaroline fosamil: a brief clinical review.

Shirley DA, Heil EL, Johnson JK.

Infect Dis Ther. 2013 Dec;2(2):95-110. doi: 10.1007/s40121-013-0010-x. Epub 2013 Aug 8.

50.

Simeprevir: a macrocyclic HCV protease inhibitor.

Talwani R, Heil EL, Gilliam BL, Temesgen Z.

Drugs Today (Barc). 2013 Dec;49(12):769-79. doi: 10.1358/dot.2013.49.12.2067249.

PMID:
24524095

Supplemental Content

Support Center